Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Intercell Supports The Japanese Encephalitis Vaccination Recommendations Of CDC's Advisory Committee On Immunization Practices
Intercell AG (VSE: ICLL) announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations and include IXIARO, a new Japanese Encephalitis (JE) vaccine for travelers to countries in Asia where the disease is endemic, as well as Americans living in such high-risk areas.
generic viagra online
Tackling Dental Access Problem About More Than Numbers, Says BDA
Research published by consumer organisation Which? highlights the well-publicised problems some patients face accessing NHS dental care, according to the British Dental Association (BDA). The consumer organisation"s research indicates that, while nine out of ten people who tried to see an NHS dentist in the last two years were successful, three million people could not get an appointment.
News of the day
Respironics Issues North American Recall Of SmartMonitor(R)2 Infant Apnea Monitor
Respironics announced today that it has voluntarily recalled 4,992 infant apnea monitors. This recall of the SmartMonitor®2 models 4002 and 4003 is being conducted due to the possibility of an audible alarm failure. Caregivers or parents who are using a SmartMonitor 2 Infant Apnea Monitor for their infant, should contact their homecare provider immediately to determine if their device is affected. However, they should continue using the apnea monitor until it is replaced, unless directed otherwise by a physician.
Nutrition

ChemGenex To Present Pivotal Data In T315I Positive CML Patients As Oral Presentation At ASCO

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral presentation at the forthcoming American Society of Clinical Oncology (ASCO) 45th Annual Meeting in Orlando, Florida. Data from the pivotal study on the use of omacetaxine in chronic myeloid leukemia (CML) patients who have failed imatinib and who harbor the T315I mutation, will be given at 11:30 am on Monday 1st June, by Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center. In addition, a poster on the company"s complementary phase 2 study investigating the potential use of omacetaxine in CML patients with resistance to multiple tyrosine kinase inhibitors (TKIs), will be presented between 5-6 pm on Friday 29th May by Dr. Meir Wetzler MD, Chief of the Division of Leukemia, School of Medicine and Biomedical Sciences, University at Buffalo, Roswell Park Cancer Institute. Commenting on today"s publication of the final program for ASCO, Greg Collier, Ph.D., Managing Director and Chief Executive Officer of ChemGenex said, "We are delighted that our late stage product candidate, omacetaxine, will be presented at a podium session during this prestigious conference." About Omacetaxine Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, and induces apoptosis by inhibition of protein synthesis, particularly Mcl-1. As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously. ChemGenex Pharmaceuticals Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009